Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

Autor: Maria Chiara Tisi, Michelina Dargenio, for Sorveglianza Epidemiologica Infezioni nelle Emopatie, Federica Lessi, Francesca Farina, Livio Pagano, Andrea Visentin, Angelica Spolzino, Luca Laurenti, Davide Facchinelli, M. Picardi, Gianpaolo Nadali, Chiara Cattaneo, Fabio Trastulli, Luisa Verga, Francesco Marchesi, Anna Candoni, Alessandro Busca, Lucia Prezioso, Gessica Marchesini, Rosa Fanci
Přispěvatelé: Marchesini, G., Nadali, G., Facchinelli, D., Candoni, A., Cattaneo, C., Laurenti, L., Fanci, R., Farina, F., Lessi, F., Visentin, A., Marchesi, F., Prezioso, L., Spolzino, A., Tisi, M. C., Trastulli, F., Picardi, M., Verga, L., Dargenio, M., Busca, A., Pagano, L.
Rok vydání: 2020
Předmět:
Male
medicine.medical_treatment
infections
lymphoproliferative diseases
targeted therapy
Targeted therapy
chemistry.chemical_compound
0302 clinical medicine
Piperidines
Risk Factors
Agammaglobulinaemia Tyrosine Kinase
Medicine
Molecular Targeted Therapy
Enzyme Inhibitors
Aged
80 and over
Bacterial Infections
Hematology
Middle Aged
Clinical Practice
Italy
Virus Diseases
030220 oncology & carcinogenesis
Ibrutinib
Female
Idelalisib
Research Paper
medicine.medical_specialty
Lymphoproliferative disorders
Opportunistic Infections
03 medical and health sciences
Internal medicine
Humans
In patient
Protein Kinase Inhibitors
lymphoproliferative disease
Aged
Quinazolinones
Retrospective Studies
business.industry
Adenine
Retrospective cohort study
medicine.disease
Haematological Malignancy – Clinical
Lymphoproliferative Disorders
infection
Settore MED/15 - MALATTIE DEL SANGUE
chemistry
Purines
Case-Control Studies
Frequent infections
business
Invasive Fungal Infections
030215 immunology
Zdroj: British Journal of Haematology
ISSN: 1365-2141
0007-1048
Popis: Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P
Databáze: OpenAIRE
Externí odkaz: